Resultados de procura - Steven D. Nathan

Limitar resultados
  1. 1
    IPF clinical trial design and endpoints

    IPF clinical trial design and endpoints por Steven D. Nathan, Keith C. Meyer

    Publicado 2014
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation

    Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation por Oksana A. Shlobin, Steven D. Nathan

    Publicado 2012
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  3. 3
    Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis

    Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis por Abhimanyu Chandel, Jean Pastré, S. Valéry, Christopher S. King, Steven D. Nathan

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics

    Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics por Andrew F. Shorr, Donald L. Helman, D. B. Davies, Steven D. Nathan

    Publicado 2005
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis

    Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis por William M. Reichmann, Yanni Yu, Dendy Macaulay, Eric Q. Wu, Steven D. Nathan

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant

    Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant por Andrew F. Shorr, Jennifer L. Wainright, Cindy Cors, Christopher J. Lettieri, Steven D. Nathan

    Publicado 2007
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis

    The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis por Christopher J. Lettieri, Steven D. Nathan, Robert Browning, Scott D. Barnett, Shahzad Ahmad, Andrew F. Shorr

    Publicado 2006
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    SERIAL MEASURES OF PULMONARY ARTERY PRESSURES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

    SERIAL MEASURES OF PULMONARY ARTERY PRESSURES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS por Steven D. Nathan, Shahzad Ahmad, James P. Koch, Scott D. Barnett, Niv Ad, Nelson A. Burton

    Publicado 2005
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Heart rate recovery after six‐minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis

    Heart rate recovery after six‐minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis por Jeffrey J. Swigris, Amy L. Olson, Oksana A. Shlobin, Shahzad Ahmad, Kevin K. Brown, Steven D. Nathan

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    The 6-min walk test as a primary end-point in interstitial lung disease

    The 6-min walk test as a primary end-point in interstitial lung disease por Sergio Harari, Athol U. Wells, Wim Wuyts, Steven D. Nathan, Klaus-Uwe Kirchgaessler, Monica Bengus, Jürgen Behr

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  11. 11
    Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis

    Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis por Stephanie Shin, Christopher S. King, Nitin Puri, Oksana A. Shlobin, Anne Brown, Shahzad Ahmad, Nargues Weir, Steven D. Nathan

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis

    Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis por Mark Fisher, Steven D. Nathan, Christian Hill, J.D. Marshall, F. Dejonckheere, Per-Olof Thuresson, Toby M. Maher

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views

    Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views por Toby M. Maher, Jeffrey J. Swigris, Michael Kreuter, Marlies Wijsenbeek, Nicola Cassidy, Lucy Ireland, Judit Axmann, Steven D. Nathan

    Publicado 2018
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Performance of the FORD Versus Other Available Models for the Noninvasive Prediction of Pulmonary Hypertension in Patients with Interstitial Lung Disease

    Performance of the FORD Versus Other Available Models for the Noninvasive Prediction of Pulmonary Hypertension in Patients with Interstitial Lung Disease por Ho Cheol Kim, Abhimanyu Chandel, Christopher S. King, Min Jee Kim, Malek Shawabkeh, Ambalavanan Arunachalam, Rade Tomic, Steven D. Nathan

    Publicado 2025
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis

    Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis por Steven D. Nathan, Ashwin Basavaraj, Cristina Reichner, Oksana A. Shlobin, Shahzad Ahmad, Joseph Kiernan, Nelson A. Burton, Scott D. Barnett

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Lung Transplantation for Patients With COVID-19

    Lung Transplantation for Patients With COVID-19 por Christopher S. King, Hannah Mannem, Jasleen Kukreja, Shambhu Aryal, Daniel Tang, Jonathan P. Singer, Ankit Bharat, Jürgen Behr, Steven D. Nathan

    Publicado 2021
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  17. 17
    The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD

    The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD por Martin Kolb, Stylianos E. Orfanos, Christopher Lambers, Kevin R. Flaherty, Alison Masters, Lisa Lancaster, Adam M. Silverstein, Steven D. Nathan

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  18. 18
    Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: Evolution of the model FORD

    Derivation and validation of a noninvasive prediction tool to identify pulmonary hypertension in patients with IPF: Evolution of the model FORD por Steven D. Nathan, Abhimanyu Chandel, Ya Wang, Jiawei Xu, Lixin Shao, Timothy R. Watkins, Jack Diviney, Christopher S. King, Ling Han

    Publicado 2023
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension

    Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Inn... por Oksana A. Shlobin, Eric Shen, Stephen J. Wort, Lucilla Piccari, John Scandurra, Paul M. Hassoun, Sylvia Nikkho, Steven D. Nathan

    Publicado 2024
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  20. 20
    Sustained Activation of Toll-Like Receptor 9 Induces an Invasive Phenotype in Lung Fibroblasts

    Sustained Activation of Toll-Like Receptor 9 Induces an Invasive Phenotype in Lung Fibroblasts por Varvara Kirillov, Jonathan T. Siler, Mahalakshmi Ramadass, Lingyin Ge, James E. Davis, Geraldine M. Grant, Steven D. Nathan, Gábor Járai, Glenda Trujillo

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: